A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
Robert P. Perrillo, Teresa Wright, Jorge Rakela, Gary Levy, Eugene Schiff, Robert Gish, Paul Martin, Jules Dienstag, Paul Adams, Rolland Dickson, Gaya Anschuetz, Steve Bell, Lynn Condreay, Nathaniel Brown, The Lamivudine North American Transplant Group – 30 December 2003 – Seventy‐seven liver transplant candidates were enrolled in a multicenter study in which patients were treated with lamivudine (100 mg daily) without the adjunctive use of hepatitis B immune globulin. Treatment was begun while patients awaited liver transplantation and continued after transplantation.